放疗联合系统治疗在乳腺癌中的应用进展

doi:10.3760/cma.j.cn371439-20230404-00072

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (6): 362-367.doi: 10.3760/cma.j.cn371439-20230404-00072

放疗联合系统治疗在乳腺癌中的应用进展

李青珊¹, 谢鑫², 张楠³(), 刘帅³()

¹潍坊医学院临床医学院，潍坊 261041
²山东第一医科大学研究生部，济南 250117
³山东第一医科大学附属中心医院乳腺疾病诊疗中心，济南 250013

收稿日期:2023-04-04 修回日期:2023-04-23 出版日期:2023-06-08 发布日期:2023-07-11
通讯作者: 张楠，Email：zlkzn2016@126.com；刘帅，Email：discoveryliu@163.com
李青珊和谢鑫对本文有同等贡献
基金资助:
山东省自然科学基金(ZR2020QH252);山东省医学会临床科研资金—齐鲁专项(YXH2022ZX02168);济南市卫生健康委员会大数据科技计划(2022-YBD-03);济南市卫生健康委员会科技计划(2020-4-24);济南市临床医学科技创新计划(202019005)

Research progress on the application of combining radiotherapy and systemic therapy in breast cancer

Li Qingshan¹, Xie Xin², Zhang Nan³(), Liu Shuai³()

¹School of Clinical Medicine，Weifang Medical University，Weifang 261041，China
²School of Graduate，Shandong First Medical University，Jinan 250117，China
³Breast Center，Central Hospital Affiliated to Shandong First Medical University，Jinan 250013，China

Received:2023-04-04 Revised:2023-04-23 Online:2023-06-08 Published:2023-07-11
Contact: Zhang Nan，Email：zlkzn2016@126.com；Liu Shuai，Email：discoveryliu@163.com
Li Qingshan and Xie Xin are contributed equally to the article
Supported by:
Natural Science Foundation of Shandong Province of China(ZR2020QH252);Clinical Research Foundation of Shandong Medical Association—Qilu Special Project(YXH2022ZX02168);Big Data Technology Plan of Jinan Municipal Health Commission(2022-YBD-03);Science and Technology Plan of Jinan Municipal Health Commission(2020-4-24);Clinical Medical Science Innovation Plan of Jinan Municipal(202019005)

摘要/Abstract

摘要：

放疗联合化疗、内分泌治疗、分子靶向治疗、免疫治疗相较于单一治疗不仅可缩短治疗周期，也可提高局部控制率，延长患者生存期，而联合治疗的安全性仍需进一步明确，以综合评估其可行性。探索放疗联合系统治疗的疗效及安全性将为临床获益患者提供依据。

关键词: 乳腺肿瘤, 放射疗法, 药物疗法, 联合, 分子靶向治疗, 免疫疗法

Abstract:

Compared with single therapy，radiotherapy combined with chemotherapy，endocrine therapy，molecular targeted therapy and immunological therapy can not only shorten the treatment cycle，but also improve the local control rate and prolong the survival of patients. However，the safety of combined therapy still needs to be further clarified to comprehensively evaluate the feasibility. Therefore，exploring the efficacy and safety of radiotherapy combined with systematic therapy will provide evidence for clinical benefits.

Key words: Breast neoplasms, Radiotherapy, Drug therapy, combination, Molecular targeted therapy, Immunotherapy

李青珊, 谢鑫, 张楠, 刘帅. 放疗联合系统治疗在乳腺癌中的应用进展[J]. 国际肿瘤学杂志, 2023, 50(6): 362-367.

Li Qingshan, Xie Xin, Zhang Nan, Liu Shuai. Research progress on the application of combining radiotherapy and systemic therapy in breast cancer[J]. Journal of International Oncology, 2023, 50(6): 362-367.

参考文献 43

[1]	Aumeeruddy MZ, Mahomoodally MF. Combating breast cancer using combination therapy with 3 phytochemicals: piperine, sulforaphane, and thymoquinone[J]. Cancer, 2019, 125(10): 1600-1611. DOI: 10.1002/cncr.32022. doi: 10.1002/cncr.32022 pmid: 30811596
[2]	Zhou ZR, Yang ZZ, Yu XL, et al. Highlights on molecular targets for radiosensitization of breast cancer cells: current research status and prospects[J]. Cancer Med, 2018, 7(7): 3110-3117. DOI: 10.1002/cam4.1588. doi: 10.1002/cam4.1588
[3]	Ciérvide R, Montero Á, García-Rico E, et al. Primary chemoradiotherapy treatment (PCRT) for HER2⁺ and triple negative breast cancer patients: a feasible combination[J]. Cancers (Basel), 2022, 14(18): 4531. DOI: 10.3390/cancers14184531. doi: 10.3390/cancers14184531
[4]	Iyer P, Radhakrishnan V, Balasubramanian A, et al. Study of pathological complete response rate with neoadjuvant concurrent chemoradiation with paclitaxel in locally advanced breast cancer[J]. Indian J Cancer, 2020, 57(4): 428-434. DOI: 10.4103/ijc.IJC_524_19. doi: 10.4103/ijc.IJC_524_19
[5]	Fernando IN, Bowden SJ, Herring K, et al. Synchronous versus sequential chemo-radiotherapy in patients with early stage breast cancer (SECRAB): a randomised, phase Ⅲ, trial[J]. Radiother Oncol, 2020, 142: 52-61. DOI: 10.1016/j.radonc.2019.10.014. doi: 10.1016/j.radonc.2019.10.014
[6]	Fernando IN, Lax S, Bowden SJ, et al. Detailed sub-study analysis of the SECRAB trial: quality of life, cosmesis and chemotherapy dose intensity[J]. Clin Oncol (R Coll Radiol), 2023, 35(6): 397-407. DOI: 10.1016/j.clon.2023.03.007. doi: 10.1016/j.clon.2023.03.007 pmid: 37012180
[7]	Ahmed S, M Kamal S, Salah T, et al. Concurrent capecitabine with external beam radiotherapy versus radiotherapy alone in painful bone metastasis of breast cancer origin[J]. J Bone Oncol, 2021, 31: 100395. DOI: 10.1016/j.jbo.2021.100395. doi: 10.1016/j.jbo.2021.100395
[8]	Cai G, Cao L, Kirova YM, et al. Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer[J]. Radiat Oncol, 2019, 14(1): 115. DOI: 10.1186/s13014-019-1321-1. doi: 10.1186/s13014-019-1321-1 pmid: 31266510
[9]	Naumann FV, Sweep FCGJ, Adema GJ, et al. Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer[J]. Cancer Metab, 2023, 11(1): 3. DOI: 10.1186/s40170-023-00304-4. doi: 10.1186/s40170-023-00304-4 pmid: 36755288
[10]	Anzic M, Marinko T. Effect of adjuvant hormonal therapy on the development of pulmonary fibrosis after postoperative radiotherapy for breast cancer[J]. J Breast Cancer, 2020, 23(5): 449-459. DOI: 10.4048/jbc.2020.23.e48. doi: 10.4048/jbc.2020.23.e48 pmid: 33154822
[11]	Elkiki SM, Mansour HH, Anis LM, et al. Evaluation of aromatase inhibitor on radiation induced pulmonary fibrosis via TGF-β/Smad 3 and TGF-β/PDGF pathways in rats[J]. Toxicol Mech Methods, 2021, 31(7): 538-545. DOI: 10.1080/15376516.2021.1934765. doi: 10.1080/15376516.2021.1934765
[12]	Chargari C, Castro-Pena P, Toledano I, et al. Concurrent use of aromatase inhibitors and hypofractionated radiation therapy[J]. World J Radiol, 2012, 4(7): 318-323. DOI: 10.4329/wjr.v4.i7.318. doi: 10.4329/wjr.v4.i7.318 pmid: 22900133
[13]	Yavas G, Yavas C, Acar H, et al. Comparison of the effects of aromatase inhibitors and tamoxifen on radiation-induced lung toxicity: results of an experimental study[J]. Support Care Cancer, 2013, 21(3): 811-817. DOI: 10.1007/s00520-012-1584-7. doi: 10.1007/s00520-012-1584-7 pmid: 22941118
[14]	Wang J, Yang Q, Haffty BG, et al. Fulvestrant radiosensitizes human estrogen receptor-positive breast cancer cells[J]. Biochem Biophys Res Commun, 2013, 431(2): 146-151. DOI: 10.1016/j.bbrc.2013.01.006. doi: 10.1016/j.bbrc.2013.01.006
[15]	Ding J, Guo Y, Jiang X, et al. Concomitant fulvestrant with reirradiation for unresectable locoregional recurrent estrogen receptor positive (ER⁺) breast cancer: a case report and narrative review[J]. Medicine (Baltimore), 2020, 99(30): e21344. DOI: 10.1097/MD.0000000000021344. doi: 10.1097/MD.0000000000021344
[16]	Belgioia L, Desideri I, Errico A, et al. Safety and efficacy of combined radiotherapy, immunotherapy and targeted agents in elderly patients: a literature review[J]. Crit Rev Oncol Hematol, 2019, 133: 163-170. DOI: 10.1016/j.critrevonc.2018.11.009. doi: S1040-8428(18)30241-5 pmid: 30661652
[17]	Beddok A, Cottu P, Fourquet A, et al. Combination of modern radiotherapy and new targeted treatments for breast cancer management[J]. Cancers (Basel), 2021, 13(24): 6358. DOI: 10.3390/cancers13246358. doi: 10.3390/cancers13246358
[18]	De Santis MC, Bonfantini F, Di Salvo F, et al. Trastuzumab and hypofractionated whole breast radiotherapy: a victorious combination?[J]. Clin Breast Cancer, 2018, 18(3): e363-e371. DOI: 10.1016/j.clbc.2017.08.011. doi: 10.1016/j.clbc.2017.08.011
[19]	Aboudaram A, Loap P, Loirat D, et al. Pertuzumab and trastuzumab combination with concomitant locoregional radiotherapy for the treatment of breast cancers with HER2 receptor overexpression[J]. Cancers (Basel), 2021, 13(19): 4790. DOI: 10.3390/cancers13194790. doi: 10.3390/cancers13194790
[20]	Lah TT, Novak M, Breznik B. Brain malignancies: glioblastoma and brain metastases[J]. Semin Cancer Biol, 2020, 60: 262-273. DOI: 10.1016/j.semcancer.2019.10.010. doi: S1044-579X(19)30227-5 pmid: 31654711
[21]	Stemmler HJ, Schmitt M, Willems A, et al. Ratio of trastuzumab levels in serum and cerebrospinal fluid is altered in HER2-positive breast cancer patients with brain metastases and impairment of blood-brain barrier[J]. Anticancer Drugs, 2007, 18(1): 23-28. DOI: 10.1097/01.cad.0000236313.50833.ee. doi: 10.1097/01.cad.0000236313.50833.ee
[22]	Mignot F, Kirova Y, Verrelle P, et al. In vitro effects of trastuzumab emtansine (T-DM1) and concurrent irradiation on HER2-positive breast cancer cells[J]. Cancer Radiother, 2021, 25(2): 126-134. DOI: 10.1016/j.canrad.2020.06.028. doi: 10.1016/j.canrad.2020.06.028 pmid: 33431297
[23]	Stumpf PK, Cittelly DM, Robin TP, et al. Combination of trastuzumab emtansine and stereotactic radiosurgery results in high rates of clinically significant radionecrosis and dysregulation of aquaporin-4[J]. Clin Cancer Res, 2019, 25(13): 3946-3953. DOI: 10.1158/1078-0432.CCR-18-2851. doi: 10.1158/1078-0432.CCR-18-2851 pmid: 30940654
[24]	Dastgheyb SS, Kim K, Doucette A, et al. Acute skin radiation toxicity seen with concurrent T-DM1: a single institutional report of 35 patients[J]. Breast, 2023, 67: 26-29. DOI: 10.1016/j.breast.2022.12.002. doi: 10.1016/j.breast.2022.12.002
[25]	Parsai S, Miller JA, Juloori A, et al. Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases[J]. J Neurosurg, 2019, 132(2): 503-511. DOI: 10.3171/2018.10.JNS182340. doi: 10.3171/2018.10.JNS182340 pmid: 30738402
[26]	Kim JM, Miller JA, Kotecha R, et al. Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis[J]. Neuro Oncol, 2019, 21(5): 659-668. DOI: 10.1093/neuonc/noz006. doi: 10.1093/neuonc/noz006
[27]	Huang T, Luo X, Wu B, et al. Pyrotinib enhances the radiosensitivity of HER2‑overexpressing gastric and breast cancer cells[J]. Oncol Rep, 2020, 44(6): 2634-2644. DOI: 10.3892/or.2020.7820. doi: 10.3892/or.2020.7820 pmid: 33125154
[28]	Anwar M, Chen Q, Ouyang D, et al. Pyrotinib treatment in patients with HER2-positive metastatic breast cancer and brain metastasis: exploratory final analysis of real-world, multicenter data[J]. Clin Cancer Res, 2021, 27(16): 4634-4641. DOI: 10.1158/1078-0432.CCR-21-0474. doi: 10.1158/1078-0432.CCR-21-0474 pmid: 34112711
[29]	Lin Y, Lin M, Zhang J, et al. Real-world data of pyrotinib-based therapy in metastatic HER2-positive breast cancer: promising efficacy in lapatinib-treated patients and in brain metastasis[J]. Cancer Res Treat, 2020, 52(4): 1059-1066. DOI: 10.4143/crt.2019.633. doi: 10.4143/crt.2019.633
[30]	Kanthou C, Tozer G. Targeting the vasculature of tumours: combi-ning VEGF pathway inhibitors with radiotherapy[J]. Br J Radiol, 2019, 92(1093): 20180405. DOI: 10.1259/bjr.20180405. doi: 10.1259/bjr.20180405
[31]	Dautruche A, Belin L, Cottu P, et al. Evaluation at 3 years of concurrent bevacizumab and radiotherapy for breast cancer: results of a prospective study[J]. Cancer Radiother, 2018, 22(3): 222-228. DOI: 10.1016/j.canrad.2017.10.004. doi: S1278-3218(18)30044-1 pmid: 29650388
[32]	Chen YL, Huang AP, Wang CC, et al. Peri-radiosurgical administration of bevacizumab improves radiographic response to single and fractionated stereotactic radiosurgery for large brain metastasis[J]. J Neurooncol, 2021, 153(3): 455-465. DOI: 10.1007/s11060-021-03782-y. doi: 10.1007/s11060-021-03782-y
[33]	Clément-Zhao A, Tanguy ML, Cottu P, et al. Toxicity of locoregional radiotherapy in combination with bevacizumab in patients with non-metastatic breast cancer (TOLERAB): final long-term evaluation[J]. PLoS One, 2019, 14(8): e0221816. DOI: 10.1371/journal.pone.0221816. doi: 10.1371/journal.pone.0221816
[34]	Pesch AM, Hirsh NH, Chandler BC, et al. Short-term CDK4/6 inhibition radiosensitizes estrogen receptor-positive breast cancers[J]. Clin Cancer Res, 2020, 26(24): 6568-6580. DOI: 10.1158/1078-0432.CCR-20-2269. doi: 10.1158/1078-0432.CCR-20-2269 pmid: 32967938
[35]	Guerini AE, Pedretti S, Salah E, et al. A single-center retrospective safety analysis of cyclin-dependent kinase 4/6 inhibitors concurrent with radiation therapy in metastatic breast cancer patients[J]. Sci Rep, 2020, 10(1): 13589. DOI: 10.1038/s41598-020-70430-2. doi: 10.1038/s41598-020-70430-2 pmid: 32788596
[36]	Beddok A, Xu HP, Henry AA, et al. Concurrent use of palbociclib and radiation therapy: single-centre experience and review of the literature[J]. Br J Cancer, 2020, 123(6): 905-908. DOI: 10.1038/s41416-020-0957-9. doi: 10.1038/s41416-020-0957-9
[37]	Michmerhuizen AR, Pesch AM, Moubadder L, et al. PARP1 inhibition radiosensitizes models of inflammatory breast cancer to ionizing radiation[J]. Mol Cancer Ther, 2019, 18(11): 2063-2073. DOI: 10.1158/1535-7163.MCT-19-0520. doi: 10.1158/1535-7163.MCT-19-0520 pmid: 31413177
[38]	Jagsi R, Griffith KA, Moran JM, et al. A randomized comparison of radiation therapy techniques in the management of node-positive breast cancer: primary outcomes analysis[J]. Int J Radiat Oncol Biol Phys, 2018, 101(5): 1149-1158. DOI: 10.1016/j.ijrobp.2018.04.075. doi: 10.1016/j.ijrobp.2018.04.075
[39]	Jagsi R, Griffith KA, Bellon JR, et al. Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: the TBCRC 024 phase Ⅰ multicenter study[J]. J Clin Oncol, 2018, 36(13): 1317-1322. DOI: 10.1200/JCO.2017.77.2665. doi: 10.1200/JCO.2017.77.2665
[40]	Loap P, Loirat D, Berger F, et al. Combination of olaparib with radiotherapy for triple-negative breast cancers: one-year toxicity report of the RADIOPARP phase Ⅰ trial[J]. Int J Cancer, 2021, 149(10): 1828-1832. DOI: 10.1002/ijc.33737. doi: 10.1002/ijc.33737
[41]	王欢, 蒋海萍, 高源, 等. 抗PD-1/PD-L1免疫治疗生物标志物研究进展[J]. 国际肿瘤学杂志, 2019, 46(1): 40-44. DOI: 10.3760/cma.j.issn.1673-422X.2019.01.009. doi: 10.3760/cma.j.issn.1673-422X.2019.01.009
[42]	Voorwerk L, Slagter M, Horlings HM, et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial[J]. Nat Med, 2019, 25(6): 920-928. DOI: 10.1038/s41591-019-0432-4. doi: 10.1038/s41591-019-0432-4 pmid: 31086347
[43]	Barroso-Sousa R, Krop IE, Trippa L, et al. A phase Ⅱ study of pembrolizumab in combination with palliative radiotherapy for hormone receptor-positive metastatic breast cancer[J]. Clin Breast Cancer, 2020, 20(3): 238-245. DOI: 10.1016/j.clbc.2020.01.012. doi: S1526-8209(20)30028-8 pmid: 32113750

放疗联合系统治疗在乳腺癌中的应用进展

Research progress on the application of combining radiotherapy and systemic therapy in breast cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 43

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王盈, 刘楠, 郭兵. 抗体药物偶联物在转移性乳腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 364-369.
[2]	高凡, 王萍, 杜超, 褚衍六. 肠道菌群与结直肠癌非手术治疗的相关研究进展[J]. 国际肿瘤学杂志, 2024, 51(6): 376-381.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	王培鑫, 赵军, 徐世红, 姜朝阳, 王小强, 杨红娟. 铁死亡相关机制在骨肉瘤中的应用进展[J]. 国际肿瘤学杂志, 2024, 51(5): 308-311.
[5]	张文馨, 夏泠, 彭晋, 周福祥. 甲胎蛋白升高型胃肝样腺癌1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 312-315.
[6]	杨毫, 施贵冬, 张程城, 张跃, 张力文, 付茂勇. 信迪利单抗与替雷利珠单抗在进展期食管鳞状细胞癌新辅助治疗中的疗效及安全性对比[J]. 国际肿瘤学杂志, 2024, 51(4): 210-216.
[7]	萨蔷, 徐航程, 王佳玉. 乳腺癌免疫治疗研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 227-234.
[8]	杨智, 陆以乔, 顾花艳, 丁佳玲, 郭贵龙. 肿瘤微环境介导乳腺癌靶向治疗耐药的研究进展[J]. 国际肿瘤学杂志, 2024, 51(4): 235-238.
[9]	张栋岩, 王品, 魏秋亚, 邓成伍, 魏相相, 高远飞, 王琛. 索凡替尼靶向联合卡培他滨和奥沙利铂治疗肝内胆管癌术后患者1例及文献复习[J]. 国际肿瘤学杂志, 2024, 51(4): 249-253.
[10]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[11]	李书月, 马辰莺, 周菊英, 徐晓婷, 秦颂兵. 寡转移非小细胞肺癌的放疗进展[J]. 国际肿瘤学杂志, 2024, 51(3): 170-174.
[12]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[13]	李济时, 陆钊群, 刘俊茹, 吕建勋, 陈霜, 沈琳, 徐志渊, 吴平安. 新辅助放疗联合部分喉切除术治疗喉滑膜肉瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(2): 123-125.
[14]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[15]	姜溪, 武永存, 梁艳, 楚丽, 段颖欣, 王力军, 霍俊杰. 派安普利单抗联合化疗对晚期非小细胞肺癌患者血管生成及循环内皮细胞的影响[J]. 国际肿瘤学杂志, 2024, 51(2): 89-94.